Upstream Bio Inc.

6.28
-0.21 (-3.24%)
At close: Apr 03, 2025, 3:59 PM
6.42
2.30%
After-hours: Apr 03, 2025, 04:43 PM EDT
-3.24%
Bid 4.68
Market Cap 336.86M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -5.58
PE Ratio (ttm) -1.13
Forward PE -4.15
Analyst Buy
Ask 7.28
Volume 201,932
Avg. Volume (20D) 251,511
Open 6.23
Previous Close 6.49
Day's Range 6.00 - 6.59
52-Week Range 5.84 - 29.46
Beta 0.49

About UPB

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in ...

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 52
Stock Exchange NASDAQ
Ticker Symbol UPB
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for UPB stock is "Buy." The 12-month stock price forecast is $56.5, which is an increase of 799.68% from the latest price.

Stock Forecasts
3 weeks ago
+7.83%
Upstream Bio shares are trading lower after the co... Unlock content with Pro Subscription
5 months ago
+8.91%
Upstream shares are trading higher after multiple firms initiated coverage on the stock with an Overweight rating.